FY2024 EPS Estimates for Illumina Lifted by Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Analysts at Leerink Partnrs increased their FY2024 EPS estimates for shares of Illumina in a report issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the life sciences company will post earnings of $4.11 per share for the year, up from their previous estimate of $4.09. The consensus estimate for Illumina’s current full-year earnings is $4.13 per share. Leerink Partnrs also issued estimates for Illumina’s Q4 2024 earnings at $0.91 EPS, Q1 2025 earnings at $0.88 EPS, Q3 2025 earnings at $1.18 EPS and FY2025 earnings at $4.30 EPS.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter last year, the company earned $0.33 EPS. Illumina’s revenue for the quarter was down 3.5% compared to the same quarter last year.

A number of other equities analysts also recently weighed in on ILMN. JPMorgan Chase & Co. boosted their target price on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Piper Sandler lowered their price objective on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Barclays raised their target price on shares of Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Robert W. Baird lifted their price target on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Finally, Citigroup lowered Illumina from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $190.00 to $165.00 in a research note on Wednesday, December 11th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Illumina has a consensus rating of “Moderate Buy” and a consensus target price of $165.63.

Illumina Stock Down 0.7 %

NASDAQ:ILMN opened at $140.36 on Wednesday. Illumina has a twelve month low of $100.08 and a twelve month high of $156.66. The firm has a market capitalization of $22.26 billion, a price-to-earnings ratio of -14.09 and a beta of 1.11. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The stock’s 50 day moving average price is $139.17 and its two-hundred day moving average price is $134.22.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ILMN. Versant Capital Management Inc increased its holdings in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares during the period. TD Private Client Wealth LLC raised its position in Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after purchasing an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its position in Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after purchasing an additional 168 shares in the last quarter. Private Trust Co. NA lifted its stake in Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 212 shares during the last quarter. Finally, Focused Wealth Management Inc acquired a new stake in shares of Illumina in the 3rd quarter valued at $63,000. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.